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Abstract: α-N-Heterocyclic thiosemicarbazones, (N)-TSCs, are potent inhibitors of ribonucleotide reductase (RR). This 
enzyme plays a critical role in DNA synthesis and repair, and is a well-recognized target for cancer chemotherapeutic 
agents. In this review the structural features of (N)-TSCs, required for maximum antitumour activity have been explored. 
Special attention is given to the mechanisms of action and structure-activity relationships. 
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1. INTRODUCTION 
 The application of Inorganic Chemistry to Medicine is a 
rapidly developing field [1]. Advances in biocoordination 
chemistry are crucial for improving the design of new anti-
tumor compounds [2-4]. Although cis-diamminedichlorido-
platinum(II), cisplatin, is a widely used anticancer drug its 
clinical utility has been limited due to the frequent develop-
ment of drug resistance, severe side effects and the limited 
spectrum of tumours against which cisplatin is active [5-7].  
 The majority of anticancer drugs exert their activity by 
inhibiting one or more processes occurring in the normal cell 
cycle. Interaction with any of the biomolecules whose nor-
mal function is necessary for cell division interrupts normal 
cellular processes resulting in cell death.  
 The most common target of many currently used chemo-
therapy drugs is DNA. There are several ways of interaction 
between DNA and a drug and they can be classified as: 1) 
formation of covalent linkage between the DNA and anti-
cancer drug. Cisplatin, which binds to DNA by coordination 
of the Pt atom to the N7 positions of two guanine bases or to 
adenine and guanine, is the best example. 2) Non-covalent 
interactions achieved through hydrogen bonding, intercala-
tion or insertion between base pairs and electrostatic interac-
tions. 3) Inhibition processes of DNA or RNA synthesis and 
repair [8-10]. 
 In recent years cancer chemotherapy has achieved impor-
tant goals. However, several tumours still have low drug 
sensitivity. Novel chemotherapeutics with marked and selec-
tive antitumor activity are essential to develop, particularly 
those that can overcome resistance to established therapies.  
 Particularly, current attention is given in the design of 
new agents with a mechanism of action different from cis- 
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platin. In this regard, of particular interest are the compounds 
targeting ribonucleotide reductase (RR), one of the most 
complex enzymes in the cell, from a biological, structural 
and regulatory point of view [11, 12].  
 α-(N)-Heterocyclic thiosemicarbazones, (N)-TSCs, are 
strong metal chelating agents and have been reported to be 
among the most effective RR inhibitors yet identified [13, 
14]. Pyridine-2-carbaldehyde thiosemicarbazone was the 
first member of this class reported to have carcinostatic ef-
fects and since then many α-N-heterocyclic thiosemicarba-
zones and their metal complexes have shown anticancer ac-
tivity against a wide spectrum of tumour cell lines. Cur-
rently, the 3-aminopyridine-2-carboxaldehyde thiosemicar-
bazone (Triapine, Vion Pharmaceuticals, New Haven, CT) is 
being evaluates in human phase II clinical trials as an anti-
neoplastic therapeutics.  
2. STRUCTURAL CHARACTERISTICS OF α-(N)-
HETEROCYCLIC THIOSEMICARBAZONES 
 Thiosemicarbazones are compounds of considerable in-
terest because of their important  chemical properties and 
potentially beneficial biological activities [15-18]. According 
to the IUPAC nomenclature [19], these compounds, usually 
obtained by condensation of an aldehyde, or a ketone with a 
thiosemicarbazide, may be named by adding the class name 
“thiosemicarbazone” after the name of the condensed alde-
hyde or ketone. In the same way bis(thiosemicarbazones) are 
derived from dicarbonyl compounds and two thiosemicar-
bazide moieties. The basic structure of thiosemicarbazone 
compounds and IUPAC numbering scheme is shown in Fig. 
(1).  
 
 
 
 
Fig. (1). Chemical structure of thiosemicarbazones. 
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 The thiosemicarbazides used in the synthesis can be ob-
tained by a series ofsynthetic procedures (Scheme 1). For 
example the reaction of hydrazine hydrate with isothiocy-
anates or  the reaction of amines with carbon disulphide fol-
lowed of the addition of hydrazine hydrate  [20]. 
 In general, the synthesis of thiosemicarbazone com-
pounds presents low cost and high atoms economy since all 
the atoms from the reagents (except water liberated in the 
condensation) are present in the final molecule. 
 Looking at the structural characteristics, thiosemicarba-
zones contain a rich set of donor atoms and are well-known 
chelators of metal ions. The coordination chemistry of thio-
semicarbazones appear to be very interesting from the point 
of view of both the number of metals forming complexes 
with them and the stabilization of various (less common) 
oxidation states of metals. Moreover many of their biological 
activities of the thiosemicarbazones often have been attrib-
uted to their ability of chelation with endogenous metals [21, 
22]. 
 Thiosemicarbazone ligands may exist as thione/thiol 
tautomeric forms owing to the intramolecular proton trans-
fer, Fig. (2). A review of thiosemicarbazone structures [23] 
shows that in solid state these molecules are almost planar, 
with the sulphur atom trans to the azomethine nitrogen atom 
(configuration E). Although there are several electronic and 
steric factors that may contribute to the adoption of this ar-
rangement, the most important is probably that the trans ar-
rangement places the amine (4N) and azomethine (1N) nitro-
gen atoms in relative positions suitable for intramolecular 
hydrogen bonding. 
 
 
 
 
Fig. (2). Tautomeric foms of thiosemicarbazones. 
 However in most of the complexes the thiosemicarba-
zone moiety coordinates to the metal ion in the cis configura-
tion through the thione/thiol atom and the azomethine nitro-
gen atom. The coordination capacity of thiosemicarbazones 
can be further increased, if the parent aldehyde or ketone 
contains additional functional group in position suitable for 
chelation. Particularly, compounds in which the thiosemicar-
bazone side-chain is attached in α position to an N-hetero-
cyclic ring, namely α-N-heterocyclic thiosemicarbazones, 
have shown substantial in vitro activity against various hu-
man tumour lines. The (N)-TSCs possess a conjugate NNS 
donor set which favour the coordination to metal ions form-
ing two five-membered chelate rings of a partially conjugate 
character and these particular structural characteristic seems 
to be essential for biological activity [24]. Moreover the 
aromatic ring can enter into the π-π interaction with bio-
molecules modifying the biological activity [25].  
 Therefore  the modification of the structure of (N)-TSC 
derivatives gives the possibility  of synthesizing novel com-
pounds and exploring their biological activities. The (N)-
TSC skeleton can be modified around three positions, Fig. 
(3): the heterocyclic ring, the 4N-substituents on the thiosemi-
carbazone moiety and chelation with metal ions. A large 
number of different (N)-TSCs, introducing structural varia-
tion have been synthesized in order to verify if the change in 
the new structural motifs have positively modulated the bio-
logical activity. 
 
 
 
 
 
 
 
 
 
Fig. (3). Modifications of α-N-heterocyclic thiosemicarbazones. 
3. MODIFICATIONS OF THE HETEROCYCLIC 
RING SYSTEMS 
 Since the initial observation of the antitumour properties 
of pyridine-2-carboxaldehyde thiosemicarbazone, Fig. 4, 
(4a), by Brockman et al. [26] a large number of different 
ring systems (benzene, furan, thiophene, etc) have been syn-
thesized and evaluated for antineoplastic activity. Among 
them, the six-membered heterocyclic ring systems carrying 
the thiosemicarbazone side-chain α to the heterocyclic nitro-
gen have shown to be the most active antineoplastic agents. 
It is interesting to note that  compounds in which the 
thiosemicarbazone moiety is affixed to the heterocyclic ring 
in the β- and γ-position relative to the ring nitrogen were 
inactive. Then, as it has been addressed above the presence 
of a NNS tridentate system is an essential structural require-
ment for the biological activity of these compounds. 
 Initially, one of the most active compounds was 5-
hydroxypyridine-2-carboxaldehyde thiosemicarbazone, Fig. 
 
 
 
 
Scheme 1. Synthetic procedures of 4N-substituted thiosemicarbazones. 
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4, (4b), which reached Phase  I clinical trials, but the impres-
sive antineoplastic activity exhibited in animal systems was 
not observed in man [27]. Its lack of activity was attributed 
to a relatively short biological half-life in humans, which 
was due to the rapid formation of an inactive O-glucoronide 
and the rapid excretion of this conjugate [28,29], accompan-
ing by high in vivo toxicity. Moreover this compound exhib-
its poor water solubility, necessary for human formulations. 
 Sartorelli et al. in 1995 [24] first reviewed the modifica-
tions concerning to the ring systems. They studied structural 
modifications of the pyridine and isoquinoline series, Fig. 4, 
(4c), in order to evaluate the effects of various substituents, 
on the heterocyclic rings, on antitumour activity. In an at-
tempt to enhance water solubility, necessary for in vivo ac-
tivity, hydrophilic groups such as amino or hydroxyl were 
introduced at various positions and found that the 3- and the 
5- amino derivatives were the most potent compounds in the 
pyridine series. For the isoquinoline series, the substitution 
of an amino group into the 5-position have been shown to be 
the best option. These new derivatives resulted resistant to 
O-glucuronidation and they were further evaluated. Among 
them, the 3-aminopyridine-2-carboxaldehyde thiosemicarba-
zone derivative, Fig. 4, (4d), appeared to be the  most prom-
ising. This compound is currently being screened for antitu-
mour effect using the National Cancer Institute panel of 60 
tumour cell lines and selected for Phase II clinical trials (Tri-
apine, Vion Pharmaceuticals, New Haven, CT;) [30-33].  
 These authors  pointed out that the replacement of the 
six-membered heterocyclic ring with five-membered ring 
systems led to a decrease or complete loss of antineoplastic 
activity. Therefore , although a large number of thiosemicar-
bazone derivatives containing five-membered heterocyclic 
rings have been synthesized and structurally characterized, 
few studies including biological activity [34, 35].  
 However we thought that the replacement of the pyridine 
ring by a 1,2,4-triazole based five-membered heterocycle 
ring [36, 37] could be a good choice  since it represents a 
hybrid of pyrazole and imidazole moieties with regard to the 
arrangement of their three donor atoms, furthermore the ad-
ditional nitrogen atom in the ring was expected to exert an 
electron-withdrawing effect, see Fig. (5).  
 
 
 
 
Fig. (5). Representation of triazole, pyrazole and imidazole. 
 The triazole heterocycle was selected not only for its 
symmetry, but also because the increased acidity of the N-H 
as a proton ionisable centre which facilitates the metal coor-
dination. So, by condensation of the diketone 3,5-diacetyl 
1,2,4-triazole with different thiosemicarbazides we have re-
cently synthesized a series of bis(thiosemicarbazone) com-
pounds which have shown in vitro, antitumour activity [38-
41].  
4. MODIFICATION OF THE THIOSEMICARBA-
ZONE SIDE CHAIN 
 Subsequent studies have involved the preparation of a 
series of homologous compounds by alterations of easily 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Structures of some α-N-heterocyclic thiosemicarbazone derivatives. 
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modifiable amine groups, since these modifications may 
cause changes in lipophilicity and structural features. It is 
worth emphasizing that replacement of the hydrogen at-
tached to the 2N by an alkyl group deactivates the compound 
as for example is observed with the 2-hydroxynaphthalene-
1-carboxaldehyde 2N-methyl-substituted thiosemicarbazone. 
This compound exhibits poor antiproliferative activity [42] 
which has been attributed to the absence of an ionisable pro-
ton on 2N, thus the formation of  the thiol tautomeric form is 
precluded and therefore  its metal binding affinity lowered. 
 In general, 4N-substituted thiosemicarbazones show re-
markable activity in comparison with the unsubstituted ones. 
An enhanced inhibitory effect may be attributed to the in-
creased lipophilicity, so they can easily cross the cell mem-
brane. 
 The 4N nitrogen of the thiosemicarbazone skeleton may 
contains: a) Two hydrogen atoms (unsubstituted thiosemi-
carbazones), b) one hydrogen atom and one alkyl or aryl 
group and c) two alkyl or aryl groups or may be a part of a 
cyclic ring. 
 Starting from the pyridine-2-carboxaldehyde thiosemi-
carbazone structure several 4N-substituted thiosemicarba-
zones related, have demonstrated significant antitumour ac-
tivity. Also, 2-acetylpyridine 4N-substituted thiosemicarba-
zones have demonstrated significant activity in a series of 
human tumour cell lines [43-48]. Following these initial re-
ports series of pyridine-2-carboxaldehyde thiosemicarbazone 
analogs have been synthesized and evaluated for antitumour 
activity [49-51]. Richardson et al. [52] have prepared 
thiosemicarbazone compounds derived from di-2-pyridyl 
ketone and 2-benzoylpyridine. These novel and patented 
compounds were found to have high antiproliferative activity 
against a number of tumour cell lines. Significantly, a num-
ber of in vivo studies using mouse models have confirmed 
the antitumor activity of the di-2-pyridylketone 4,4-dimethyl-
thiosemicarbazone, Fig. 4, (4e).  
 Also a series of α-N-heterocyclic bi(thiosemicarbazones)  
was also explored. These derivatives, namely bis(thiosemicar-
bazones), having the two thiosemicarbazone moieties posi-
tioned in the molecule are much more powerful metal-
chelating agents [53].  
 Within the class of α-N-heterocyclic bis(thiosemicar-
bazones), 2,6-diacetylpyridine bis(thiosemicarbazone) deri-
vatives have been described as promising antitumour agents 
[54]. Also, a series of 3,5-diacetyl-1,2,4-triazol 4N-substi-
tuted bis(thiosemicarbazone) ligands synthesized in our labo-
ratory have showed in vivo antitumour activity Fig.  (6). In 
this case the activity of the ligands increase with the size and 
shape of the hydrophobic substitution on 4N of the thiosemi-
carbazone moieties [41].  
5. METAL COMPLEXES AND STRUCTURE–
ACTIVITY RELATIONSHIPS 
 It has been widely acknowledged that the α-N-Hetero-
cyclic thiosemicarbazones are strong metal chelating agents. 
Generally react with metal ions to form 1:1 or 2:1 ligand-to-
metal complexes, depending upon the coordination number 
of the metal. Several (N)-TSCs metal complexes have shown 
significant biological activity, suggesting accessibility of 
coordination site, a fundamental requirement for biological 
activity by the complexes. Recently the structure trends of 
metal thiosemicarbazones have been reviewed [55], most of 
the complexes studied are mononuclear or dinuclear and 
with only a few complexes of higher nuclearity.  
 Petering and co-workers [56] first demonstrated that 
some iron o copper α-N-heterocyclic thiosemicarbazone 
chelates were more potent than the free ligands, the same 
effect has been observed later with other essential metals 
such zinc [57-59].  
 Recently Keppler and co-workers have reported a num-
ber of Ga(III) and Ru(II) (N)-TSCs complexes with potent 
antiproliferative properties [60,61]. Also, a recent publica-
tion of Beraldo et al. reports the cytotoxic activity of Ga(III) 
complexes of 2-pyridineformamide thiosemicarbazones [62].  
 Other works have demonstrated that complexation of 
(N)-TSCs with metal ions like platinum(II) or palladium(II) 
that damage DNA produces synergetic inhibition of tumour 
growth [63,64]. So, the synthesis, spectral and structural 
characterization and antitumour activity of a vast number of 
transition-metal α-N-heterocyclic thiosemicarbazone com-
plexes have been reported [65, 66].  
Our recent work in this area has focused on palladium y 
platinum complexes derived from 3,5-diacetyl-1,2,4-triazol 
bis(4N-substituted-thiosemicarbazones), Tz(NHR-TSC)2 [41].  
X-Ray data have been obtained for many of these com-
pounds. These complexes are characterized by their dinuc-
lear structure which results of the pairing of two mononu-
clear units through two thiosemicarbazone bridges, the 
whole molecule containing  two parallel coordination planes  
are stabilized by the presence of π-π stacking interactions.  
 The antitumor activity revealed that this series of com-
pounds are active  toward the cancer cell lines tested (A2780 
and A2780cisR), the results obtained are shown in Table 1.  
 The structure-activity relationships study revealed that in 
general, activity increases with the increasing size of the 4N 
substituent but one exception was found,  namely most cyto-
toxic ligand (4N-phenyl substituted)  generated a weak cyto-
toxic platinum complex and an inactive palladium one. 
Based on the monocrystal X-ray structure of the ligand (al-
most planar except one of the two phenyl groups) this drastic 
change in the activity was explained in terms of the struc-
tural changes produced upon the complexation like the pres-
 
 
 
 
 
Fig. (6). Schematic representation of 3,5-diacetyl-1,2,4-triazol 
bis(thiosemicarbazones). 
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ence of four bulky phenyl groups which sterically hinder 
interactions and also prevent direct hydrogen bonding with 
biological molecules.  
 The study of this family of compounds also points to the 
influence of  the nature of the metal ion that appears affect to 
the biological activity of this series since some palladium 
complexes displayed slightly higher activity than platinum 
ones. Taking in account that palladium(II) and platinum(II) 
complexes have high thermodynamic stability especially 
with bidentate sulphur-nitrogen chelating agents but the 
platinum complexes are too kinetically inert (in regard to 
ligand exchange) whereas the palladium complexes are ki-
netically labile, it might be concluded  that  the higher ki-
netic lability of the palladium complexes make them more 
suitable for interacting with the cancer cells.  
 This series of compounds was active not only in the epi-
thelian human ovarian cancer, cisplatin sensitive, A2780 cell 
line but also in the A2780cisR, cisplatin resistant, cell line. It 
has been shown that cellular thiols can sequester cisplatin, 
leading to a reduction in the levels of cisplatin-DNA damage 
however, some studies have demonstrated that thiosemicar-
bazone complexes having sulphur coordinated do not react 
with cellular thiols [67]. 
6. MECHANISMS OF ACTIONS 
 As a result of the extensive biological and chemical stud-
ies carried out on (N)-TSCs, the enzyme ribonucleotide re-
ductase, RR, has been identified to be  the principal target of 
the α-N-heterocyclic thiosemicarbazones[68]. 
 The enzyme RR which catalyzes the conversion of ribo-
nucleotides into desoxyribonucleotides during DNA synthe-
sis, is highly expressed in tumour cells making it a suitable 
and well-established target for cancer therapy. 
 Mammalian ribonucleotide reductase (RR) is composed 
of two dissimilar proteins, (R1) which contains polythiols 
and (R2), which contains non-heme iron and a free tyrosyl 
radical.  The only known R2 requirement for the enzymatic 
activity of the  RR is the presence of a tyrosyl free radical, 
which represents the one-electron oxidized state of a tyrosine 
residue. Formation and stability of the radical depends on the 
binuclear Fe(III) center, found both in E. coli and mammal-
ian R2 [69, 70]. 
 The α-N-heterocyclic thiosemicarbazones are known iron 
chelators and as such can bind intracellular iron and/or dam-
age the non-heme iron-stabilized tyrosyl free radical and thus 
inhibit the catalytical function of RR (Scheme 2).  
 An important aspect that requires discussion is that (N)-
TSCs are capable not only of bind Fe but also form redox-
active iron complexes that are though to play an important 
role in their anti-proliferative efficacy. Thelander and Gräs-
lund demonstrated for the first time that destruction of the 
tyrosyl radical by a (N)-TSC requires iron and oxygen [71]. 
Since then many authors have carried  out studies on the 
redox  active (N)-TSC iron complexes [72,73]. 
 Recently, Richardson et al. have examined the mecha-
nism of action of the di-2-pyridylketone-4,4-dimethyl-3-
thiosemicarbazone molecule and have shown that the an-
tileukemic activity of this compound is mediated, at least in 
part, by its ability to bind cancer cell iron, forming a redox-
active iron complex that generates reactive oxygen species 
[74].  
 It is assumed that, in general, complexation to metal ions 
increases the tumour-inhibition activity of the (N)-TSCs and 
this suggests that the mechanism of action of (N)-TSC com-
plexes is not only due to the inhibition of RR but both the 
metal and the ligand determine the biological activity. In-
Table 1. IC50±SD (µM) and Resistance Factor (RF) Values Obtained for 3,5-diacetyl-1,2,4-triazol bis(thiosemicarbazone), 
Tz(NHR-TSC)2, Series with Respect to Cisplatin in the Human Ovarian Carcinoma Cell-Lines Sensitive and Resistant to 
Cisplatin (A2780 and A2780cisR) 
 IC50(A2780) IC50(A2780cisR) RF* 
Tz(NHPh-TSC)2 1 
Tz(NH2-TSC)2 2 
Tz(NHMe-TSC)2 3 
Tz(NHEt-TSC)2 4 
[Pd-Tz(NHPh-TSC)2]2  5 
[Pd- Tz(NH2-TSC)2]2  6 
[Pd- Tz(NHMe-TSC)2]2 7 
[Pd-Tz(NHEt-TSC)2]2 8 
[Pt –Tz(NHPh-TSC)2]2  9 
[Pt- Tz(NH2-TSC)2]2  10 
[Pt-Tz(NHMe-TSC)2]2 11 
[Pt-Tz(NHEt-TSC)2]2 12 
Cisplatin 
6.2±0.3 
>100 
39±2 
35±2 
>100 
>100 
15±2 
25±2 
40±2 
50±5 
40±2 
63±2 
0.44±0.04 
5.4±0.4 
>100 
>100 
46±2 
>100 
>100 
18±2 
10±2 
>100 
>100 
56±3 
66±5 
4.7±0.3 
0.87 
--- 
--- 
1.31 
--- 
--- 
1.20 
0.40 
--- 
--- 
1.40 
1.05 
10.7 
* RF = IC50(A2780cisR) / IC50(A2780). 
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deed,  the metal compounds could act through dual or even 
multiple mechanisms of action by combining the pharmacol-
ogical properties of both, the ligand and the metal. 
 Platinum(II) attacks DNA, but other metal ions may have 
different targets sites. For example, it has been demonstrated 
that iron and copper (N)-TSC complexes are readily reduced 
by thiol compounds and oxidized by oxygen or by reduced 
species of oxygen to produce reactive entities, including 
oxygen radicals which cause tissue damage [69,70]. Gallium 
affects intracelular iron availability due to the competitive 
binding of gallium(III) and iron(III) toward bioligands but 
also interacts directly with RR displacing iron from the R2 
subunit of this enzyme [74].  
 In conclusion, in this review the structural features of 
(N)-TSCs required for maximum activity have been pointed 
out thus constituting  a good example of how small changes 
in molecular structure could lead to profound differences in 
biological activity. Since the mechanism of action of (N)-
TSCs is different from established chemotherapies, they ap-
pear to be good candidates particularly for  use in combina-
tion therapy. It is important to note that several combinations 
of (N)-TSCs, like Triapine®, with other anticancer drugs 
have been reported to give additive or synergistic activity. 
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